D-0097-2019 Class II Terminated

Recalled by Teva Pharmaceuticals USA — North Wales, PA

FDA drug recall D-0097-2019 was initiated by Teva Pharmaceuticals USA on Aug 6, 2018 and is designated Class II. Reason for recall: Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release. The recall status is terminated (terminated Feb 13, 2020). Affected quantity: 3,785 bottles.

Recall Details

Product Type
Drugs
Report Date
Oct 31, 2018
Initiation Date
Aug 6, 2018
Termination Date
Feb 13, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3,785 bottles

Product Description

Paliperidone Extended Release Tablets 9 mg, packaged in a) 30-count bottle(NDC 0591-3695-30) , b) 90-count bottle (NDC 0591-3695-19), Rx only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054

Reason for Recall

Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.

Distribution Pattern

Product was distributed throughout the United States. Bulk product was distributed to Takeda, Deerfield, IL and may have been further distributed.

Code Information

Lot #: a) 1291192A, Exp 01/2020; b) 1291193A, Exp 01/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0097-2019
openFDA file date
Oct 23, 2026
Loaded by RegDataLab
Oct 24, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.